Cellyan Biotechnology (HKPD) Operating Leases (2024 - 2026)
Cellyan Biotechnology (HKPD) posted quarterly Operating Leases of $129713.0 for Q3 2025, down 35.39% year-over-year from $200759.0 in Q3 2024, and up 1922.97% quarter-over-quarter from $6412.0 in Q1 2025.
Cellyan Biotechnology (HKPD) Operating Leases (2024 - 2026) Analysis & Trends
Cellyan Biotechnology (HKPD) has reported Operating Leases for 2 consecutive years, with $129713.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Operating Leases fell 35.39% year-over-year to $129713.0; the TTM figure through Sep 2025 stood at $129713.0 (down 35.39% YoY), while the FY2025 annual figure was $6412.0, down 94.56% from the prior year.
- Operating Leases improved to $129713.0 in Q3 2025 per HKPD's latest filing, from $6412.0 in the prior quarter.
- Across five years, Operating Leases topped out at $200759.0 in Q3 2024 and bottomed at $6412.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Mckesson | 100.02 Bn | 94.85 Bn | 3.69 Bn |
| 2 | Cencora | 60.88 Bn | 58.06 Bn | 3.61 Bn |
| 3 | Cardinal Health | 54.14 Bn | 49.29 Bn | 2.56 Bn |
| 4 | Henry Schein | 10.05 Bn | 9.90 Bn | 1.10 Bn |
| 5 | Akso Health | 737.16 Mn | 736.96 Mn | - |
| 6 | Edap Tms | 159.12 Mn | 137.58 Mn | 7.34 Mn |
| 7 | Accendra Health | 100.85 Mn | 93.20 Mn | 263.41 Mn |
| 8 | 111 | 32.10 Mn | -26.65 Mn | 18.18 Mn |
| 9 | Cosmos Health | 12.73 Mn | 10.29 Mn | 1.51 Mn |
| 10 | Cellyan Biotechnology | 6.55 Mn | 6.32 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 65,275.00 |
| Sep 30, 2025 | 129,713.00 |
| Mar 31, 2025 | 6,412.00 |
| Sep 30, 2024 | 200,759.00 |
| Mar 31, 2024 | 117,836.00 |